CLINICAL AND MORPHOLOGICAL FEATURES OF HEREDITARY OVARIAN CANCER

Oral contraceptives and the risk of hereditary ovarian cancer. Hereditary Ovarian Cancer Clinical Study Group.

BACKGROUND Women with mutations in either the BRCA1 or the BRCA2 gene have a high lifetime risk of ovarian cancer. Oral contraceptives protect against ovarian cancer in general, but it is not known whether they also protect against hereditary forms of ovarian cancer. METHODS We enrolled 207 women with hereditary ovarian cancer and 161 of their sisters as controls in a case-control study. All ...

Clinical, Molecular and Geographical Features of Hereditary Breast/Ovarian Cancer in Latvia

INTRODUCTION The aim of the study is to evaluate the incidence and phenotype-genotype characteristics of hereditary breast and ovarian cancer syndromes in Latvia in order to develop the basis of clinical management for patients and their relatives affected by this syndrome. MATERIALS AND METHODS In 2002-2004 in two Latvian oncology hospitals (Liepãja Oncology Hospital and Daugavpils Oncology ...

Hereditary Breast and Ovarian Cancer – Current Clinical Guidelines in Germany

Zusammenfassung Etwa 5–10% aller Mammaund Ovarialkarzinome sind durch Keimbahnmutationen in bekannten Hochrisikogenen wie BRCA1 oder BRCA2 zurückzuführen. Ein beachtlicher Anteil von Familien mit einer gehäuften Erkrankungsrate weist jedoch keine Mutationen in den bekannten Risikogenen auf. In Deutschland werden seit 2005 die Kosten für genetische Tests und intensivierte Früherkennungsuntersuch...

SEOM clinical guidelines in Hereditary Breast and ovarian cancer

Approximately, 7 % of all breast cancers (BC) and 11-15 % of ovarian cancers (OC) are associated with inherited predisposition, mainly related to germline mutations in high penetrance BRCA1/2 genes. Clinical criteria for genetic testing are based on personal and family history to estimate a minimum 10 % detection rate. Selection criteria are evolving according to new advances in this field and ...

Hereditary Breast-Ovarian Cancer